Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
    • Transkriptioner
  • InderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Bolag under bevakning
    • Teamet
Pressmeddelande

Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Simris Group

Simris Group AB (“Simris” or the “Company”) has entered into a Memorandum of Understanding (“MoU”) with Immunrise Biocontrol France SAS (“Immunrise”) regarding a potential divestment of the Company’s assets related to microalgae production in Hammenhög, Sweden.

The MoU concerns all assets associated with Simris’ production facility for microalgae in Hammenhög. The parties have agreed on an indicative valuation principle whereby the purchase price is expected to be in line with the book value of the assets, subject to satisfactory completion of legal, technical and operational due diligence, as well as the negotiation and execution of a definitive asset purchase agreement.

Under the MoU, Immunrise intends to conduct due diligence with the objective of submitting a firm and binding offer no later than 1 March 2026. Subject to the outcome of the process, the parties aim to enter into a definitive agreement by 31 March 2026.

The MoU includes customary provisions on exclusivity and confidentiality, which are binding on the parties. Apart from these provisions, the MoU does not constitute a binding commitment to complete the transaction. There can be no assurance that a definitive agreement will be entered into or that the transaction will be completed.

The Board of Directors of Simris considers the potential transaction to be aligned with the Company’s strategic priorities and, if completed, to have the potential to strengthen the Company’s financial position and strategic focus.

Further information will be communicated as the process progresses.

Contact Details:
Daniel Kubitza
Interim CEO of Simris Group AB
Email: daniel.kubitza@simris.com
Mobile: +33 6 71 04 21 52
www.simrisgroup.com

About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. 

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments
Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.